HK1208817A1 - Chromane compounds - Google Patents

Chromane compounds Download PDF

Info

Publication number
HK1208817A1
HK1208817A1 HK15109582.8A HK15109582A HK1208817A1 HK 1208817 A1 HK1208817 A1 HK 1208817A1 HK 15109582 A HK15109582 A HK 15109582A HK 1208817 A1 HK1208817 A1 HK 1208817A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
alzheimer
disease
preventing
treating diseases
Prior art date
Application number
HK15109582.8A
Other languages
English (en)
Chinese (zh)
Inventor
Ryosuke Munakata
Makoto Inoue
Hiroaki Tominaga
Shingo Yamasaki
Yasuhiro Shiina
Kiyohiro Samizu
Hisao Hamaguchi
Lin Hong
Original Assignee
Comentis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Comentis, Inc. filed Critical Comentis, Inc.
Publication of HK1208817A1 publication Critical patent/HK1208817A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
HK15109582.8A 2012-05-30 2013-05-29 Chromane compounds HK1208817A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261653321P 2012-05-30 2012-05-30
US61/653,321 2012-05-30
US201361782038P 2013-03-14 2013-03-14
US61/782,038 2013-03-14
PCT/US2013/043016 WO2013181202A2 (en) 2012-05-30 2013-05-29 Chromane compounds

Publications (1)

Publication Number Publication Date
HK1208817A1 true HK1208817A1 (en) 2016-03-18

Family

ID=49674034

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109582.8A HK1208817A1 (en) 2012-05-30 2013-05-29 Chromane compounds

Country Status (15)

Country Link
US (2) US8975415B2 (https=)
EP (1) EP2854797A4 (https=)
JP (1) JP2015518048A (https=)
KR (1) KR20150023536A (https=)
CN (1) CN104394862A (https=)
AR (1) AR091203A1 (https=)
AU (1) AU2013267555A1 (https=)
BR (1) BR112014029597A2 (https=)
CA (1) CA2873678A1 (https=)
EA (1) EA026380B1 (https=)
HK (1) HK1208817A1 (https=)
MX (1) MX2014014066A (https=)
SG (1) SG11201407796YA (https=)
TW (1) TW201408672A (https=)
WO (1) WO2013181202A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015518048A (ja) 2012-05-30 2015-06-25 コメンティス， インコーポレイテッド クロマン化合物
TW201629025A (zh) * 2014-10-07 2016-08-16 阿斯特捷利康公司 化合物及其作為ｂａｃｅ抑制劑之用途
CN110818694B (zh) * 2019-11-18 2023-04-21 上海医药工业研究院有限公司 艾拉普林中间体及其应用
CN110724135B (zh) * 2019-11-18 2023-04-28 上海医药工业研究院有限公司 一种艾拉普林中间体及其制备方法
CN110713483B (zh) * 2019-11-18 2023-04-07 上海医药工业研究院 艾拉普林中间体及艾拉普林的制备方法
CN110790753B (zh) * 2019-11-18 2023-04-07 上海医药工业研究院 艾拉普林对甲苯磺酸盐、其制备方法和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1196609A2 (en) 1999-06-28 2002-04-17 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
US20040121947A1 (en) 2000-12-28 2004-06-24 Oklahoma Medical Research Foundation Compounds which inhibit beta-secretase activity and methods of use thereof
CA2464736A1 (en) 2001-10-23 2003-05-15 Oklahoma Medical Research Foundation Beta-secretase inhibitors and methods of use
PT1699455E (pt) 2003-12-15 2013-08-27 Merck Sharp & Dohme Inibidores de protease de aspartilo heterocíclicos
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
EP2318416B1 (en) 2008-07-28 2013-09-04 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
WO2010013302A1 (ja) * 2008-07-28 2010-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
JP5444240B2 (ja) * 2008-07-28 2014-03-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
US8450308B2 (en) * 2008-08-19 2013-05-28 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
CA2736130C (en) * 2008-09-11 2014-01-14 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use
CA2753730C (en) * 2009-03-13 2020-12-22 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
US8461160B2 (en) 2009-05-08 2013-06-11 Hoffmann-La Roche, Inc. Dihydropyrimidinones
WO2011072064A1 (en) * 2009-12-08 2011-06-16 Array Biopharma Inc. S piro [chroman - 4, 4 ' - imidazol] ones as beta - secretase inhibitors
CN102812005B (zh) * 2010-02-24 2014-12-10 生命医药公司 β-分泌酶抑制剂
EP2547685A1 (en) * 2010-03-15 2013-01-23 Amgen Inc. Spiro-tetracyclic ring compounds as beta - secretase modulators
MX2012010657A (es) * 2010-03-15 2013-02-07 Amgen Inc Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico.
US20120065195A1 (en) * 2010-03-31 2012-03-15 Clark Christopher T Compounds for treating neurodegenerative diseases
WO2011130741A1 (en) 2010-04-16 2011-10-20 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
US20120083501A1 (en) 2010-09-24 2012-04-05 Hunt Kevin W Compounds for treating neurodegenerative diseases
TW201300380A (zh) 2010-10-19 2013-01-01 Comentis Inc 抑制β－分泌酶活性之噁二唑化合物及其使用方法
WO2012071458A1 (en) 2010-11-22 2012-05-31 Array Biopharma Inc. Heterocyclic inhibitors of beta - secretase for the treatment of neurodegenerative diseases
EP2643325A1 (en) 2010-11-23 2013-10-02 Amgen Inc. Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
EP2673279A1 (en) 2011-02-07 2013-12-18 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use
EP2675810A1 (en) 2011-02-15 2013-12-25 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
US9079919B2 (en) 2011-05-27 2015-07-14 Hoffmann-La Roche Inc. Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
EP2780321B1 (en) 2011-10-10 2015-12-30 Astrazeneca AB Mono-fluoro beta-secretase inhibitors
JP2015518048A (ja) 2012-05-30 2015-06-25 コメンティス， インコーポレイテッド クロマン化合物
EP2669286A1 (en) 2012-05-31 2013-12-04 Ares Trading S.A. Spiro tetrahydro-benzothiophen derivatives useful for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
US20150225386A1 (en) 2015-08-13
AU2013267555A1 (en) 2014-12-04
US8975415B2 (en) 2015-03-10
EA026380B1 (ru) 2017-04-28
TW201408672A (zh) 2014-03-01
KR20150023536A (ko) 2015-03-05
EP2854797A4 (en) 2016-01-13
US9242973B2 (en) 2016-01-26
EA201492271A1 (ru) 2015-10-30
EP2854797A2 (en) 2015-04-08
US20140179695A1 (en) 2014-06-26
JP2015518048A (ja) 2015-06-25
CN104394862A (zh) 2015-03-04
CA2873678A1 (en) 2013-12-05
BR112014029597A2 (pt) 2017-11-07
WO2013181202A3 (en) 2014-01-30
MX2014014066A (es) 2015-03-19
WO2013181202A2 (en) 2013-12-05
SG11201407796YA (en) 2014-12-30
AR091203A1 (es) 2015-01-21

Similar Documents

Publication Publication Date Title
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2013181202A3 (en) Chromane compounds
WO2014093114A8 (en) Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
WO2013134085A8 (en) Inhibitors of beta-secretase
WO2013033037A3 (en) Novel antiprion compounds
BR112013031510A2 (pt) [1,3]oxazinas
WO2011106729A3 (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
PH12014501334A1 (en) Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines
WO2010107807A3 (en) Compounds for treating inflammation and pain
WO2011159124A3 (ko) Ｉｎｔｅｒｌｅｕｋｉｎ-６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
BR112014028813A2 (pt) 5-amino[1,4]tiazinas como inibidores bace1
WO2014036502A8 (en) Tetracycline compounds
EP2542085A4 (en) COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDER
EA201591021A1 (ru) 4-гидрокси-2-метил-5-(пропан-2-илиден)циклогекс-3-энекарбальдегид в профилактике и лечении когнитивных, нейродегенеративных или нейронных заболеваний
WO2010019911A3 (en) 1,4-benzoxazine compounds and derivatives thereof as therapeutic drugs for the treatment of neurodegenerative conditions
MX350145B (es) Extracto proteolitico a partir de bromelaina para el tratamiento de trastornos del tejido conectivo.
WO2012103282A3 (en) Methods and compositions for treating alzheimer's disease
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
WO2014001363A8 (en) Novel tetrazole derivatives and their use as potassium channel modulators
WO2013181217A3 (en) Novel compounds and compositions for treatment of breathing control disorders or diseases
MX2016006906A (es) 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas.
WO2014006571A3 (en) Extended-release pharmaceutical dosage forms of carbidopa and levodopa and processes of preparation thereof
WO2012038850A8 (en) Pyrimidones for treatment of potassium channel related diseases
WO2012125663A3 (en) Cyclohexane substituted amino cyclopentane derivatives as useful ccr2 antagonists